Cargando…

Cell therapy for type 1 diabetes

Cell therapy in the form of human islet transplantation has been a successful form of treatment for patients with type 1 diabetes for over 10 years, but is significantly limited by lack of suitable donor material. A replenishable supply of insulin-producing cells has the potential to address this pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Muir, K.R., Lima, M.J., Docherty, H.M., Docherty, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969521/
https://www.ncbi.nlm.nih.gov/pubmed/24481872
http://dx.doi.org/10.1093/qjmed/hcu025
_version_ 1782309274172522496
author Muir, K.R.
Lima, M.J.
Docherty, H.M.
Docherty, K.
author_facet Muir, K.R.
Lima, M.J.
Docherty, H.M.
Docherty, K.
author_sort Muir, K.R.
collection PubMed
description Cell therapy in the form of human islet transplantation has been a successful form of treatment for patients with type 1 diabetes for over 10 years, but is significantly limited by lack of suitable donor material. A replenishable supply of insulin-producing cells has the potential to address this problem; however to date success has been limited to a few preclinical studies. Two of the most promising strategies include differentiation of embryonic stem cells and induced pluripotent stem cells towards insulin-producing cells and transdifferentiation of acinar or other closely related cell types towards β-cells. Here, we discuss recent progress and challenges that need to be overcome in taking cell therapy to the clinic.
format Online
Article
Text
id pubmed-3969521
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-39695212014-03-31 Cell therapy for type 1 diabetes Muir, K.R. Lima, M.J. Docherty, H.M. Docherty, K. QJM Reviews Cell therapy in the form of human islet transplantation has been a successful form of treatment for patients with type 1 diabetes for over 10 years, but is significantly limited by lack of suitable donor material. A replenishable supply of insulin-producing cells has the potential to address this problem; however to date success has been limited to a few preclinical studies. Two of the most promising strategies include differentiation of embryonic stem cells and induced pluripotent stem cells towards insulin-producing cells and transdifferentiation of acinar or other closely related cell types towards β-cells. Here, we discuss recent progress and challenges that need to be overcome in taking cell therapy to the clinic. Oxford University Press 2014-04 2014-03-07 /pmc/articles/PMC3969521/ /pubmed/24481872 http://dx.doi.org/10.1093/qjmed/hcu025 Text en © The Author 2014. Published by Oxford University Press on behalf of the Association of Physicians. http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Muir, K.R.
Lima, M.J.
Docherty, H.M.
Docherty, K.
Cell therapy for type 1 diabetes
title Cell therapy for type 1 diabetes
title_full Cell therapy for type 1 diabetes
title_fullStr Cell therapy for type 1 diabetes
title_full_unstemmed Cell therapy for type 1 diabetes
title_short Cell therapy for type 1 diabetes
title_sort cell therapy for type 1 diabetes
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969521/
https://www.ncbi.nlm.nih.gov/pubmed/24481872
http://dx.doi.org/10.1093/qjmed/hcu025
work_keys_str_mv AT muirkr celltherapyfortype1diabetes
AT limamj celltherapyfortype1diabetes
AT dochertyhm celltherapyfortype1diabetes
AT dochertyk celltherapyfortype1diabetes